CoChat
Sign Up
Cited by 163

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease

Zissimopoulos, Julie M., Barthold, Douglas, Brinton, Roberta Diaz, Joyce, Geoffrey·2017·JAMA Neurology
DOI 10.1001/jamaneurol.2016.3783PMC PMC5646357
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2016.3783

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 31

  1. [1]Gu Q Paulose-Ram R Burt VL Kit BK Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003–2012 https://www.cdc.gov/nchs/data/databriefs/db177.pdf. Published December 2014 Accessed March 30, 2016 25536410
  2. [2]Chong PH Seeger JD Franklin C Clinically relevant differences between the statins: implications for therapeutic selection Am J Med 2001 111 5 390 400 11583643
  3. [3]Kandiah N Feldman HH Therapeutic potential of statins in Alzheimer’s disease J Neurol Sci 2009 283 1–2 230 234 19321181
  4. [5]Lesser GT Beeri MS Schmeidler J Purohit DP Haroutunian V Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles Curr Alzheimer Res 2011 8 3 303 312 21244352 PMC3267087
  5. [6]Petanceska SS DeRosa S Olm V Statin therapy for Alzheimer’s disease: will it work? J Mol Neurosci 2002 19 1–2 155 161 12212773
  6. [7]Refolo LM Pappolla MA LaFrancois J A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer’s disease Neurobiol Dis 2001 8 5 890 899 11592856
  7. [8]Petanceska SS DeRosa S Sharma A Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol J Mol Neurosci 2003 20 3 395 406 14501024
  8. [9]McGuinness B Passmore P Can statins prevent or help treat Alzheimer’s disease? J Alzheimers Dis 2010 20 3 925 933 20182019
  9. [10]Caballero J Nahata M Do statins slow down Alzheimer’s disease? a review J Clin Pharm Ther 2004 29 3 209 213 15153082
  10. [11]Jukema JW Cannon CP de Craen AJ Westendorp RG Trompet S The controversies of statin therapy: weighing the evidence J Am Coll Cardiol 2012 60 10 875 881 22902202
  11. [13]Shepardson NE Shankar GM Selkoe DJ Cholesterol level and statin use in Alzheimer disease: II, review of human trials and recommendations Arch Neurol 2011 68 11 1385 1392 22084122 PMC3248784
  12. [14]McGuinness B Craig D Bullock R Passmore P Statins for the prevention of dementia [published online January 4, 2016] Cochrane Database Syst Rev 10.1002/14651858.CD003160.pub3 PMC9346344 26727124 · DOI · Paper page
  13. [15]Haag MD Hofman A Koudstaal PJ Stricker BH Breteler MM Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity: the Rotterdam Study J Neurol Neurosurg Psychiatry 2009 80 1 13 17 18931004
  14. [16]Hendrie HC Hake A Lane K Statin use, incident dementia and Alzheimer disease in elderly African Americans Ethn Dis 2015 25 3 345 354 26673814 PMC4671419
  15. [17]Jick H Zornberg GL Jick SS Seshadri S Drachman DA Statins and the risk of dementia Lancet 2000 356 9242 1627 1631 11089820
  16. [18]Li G Shofer JB Rhew IC Age-varying association between statin use and incident Alzheimer’s disease J Am Geriatr Soc 2010 58 7 1311 1317 20533968 PMC3176730
  17. [19]Lin F-C Chuang Y-S Hsieh H-M Early statin use and the progression of Alzheimer disease: a total population-based case-control study Medicine (Baltimore) 2015 94 47 e2143 26632742 PMC5059011
  18. [20]Wolozin B Wang SW Li N-C Lee A Lee TA Kazis LE Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease BMC Med 2007 5 1 20 17640385 PMC1955446
  19. [21]Blackwell M Iacus S King G Porro G Cem: coarsened exact matching in Stata Stata J 2009 9 4 524 546 http://www.stata-journal.com/sjpdf.html?articlenum=st0176 Accessed April 25, 2016
  20. [22]Li P Kim MM Doshi JA Comparison of the performance of the CMS Hierarchical Condition Category (CMS-HCC) risk adjuster with the Charlson and Elixhauser comorbidity measures in predicting mortality BMC Health Serv Res 2010 10 1 245 20727154 PMC2936901
  21. [24]Vuletic S Riekse RG Marcovina SM Peskind ER Hazzard WR Albers JJ Statins of different brain penetrability differentially affect CSF PLTP activity Dement Geriatr Cogn Disord 2006 22 5–6 392 398 16960448
  22. [25]Simons M Keller P Dichgans J Schulz JB Cholesterol and Alzheimer’s disease: is there a link? Neurology 2001 57 6 1089 1093 11571339
  23. [26]Sano M Bell KL Galasko D A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease Neurology 2011 77 6 556 563 21795660 PMC3149154
  24. [27]Zandi PP Sparks DL Khachaturian AS Cache County Study investigators. Do statins reduce risk of incident dementia and Alzheimer disease? the Cache County Study Arch Gen Psychiatry 2005 62 2 217 224 15699299
  25. [28]Shepardson NE Shankar GM Selkoe DJ Cholesterol level and statin use in Alzheimer disease: I, review of epidemiological and preclinical studies Arch Neurol 2011 68 10 1239 1244 21987540 PMC3211071
  26. [29]Mangravite LM Thorn CF Krauss RM Clinical implications of pharmacogenomics of statin treatment Pharmacogenomics J 2006 6 6 360 374 16550210
  27. [30]Warnich L Drögemöller BI Pepper MS Dandara C Wright GE Pharmacogenomic research in South Africa: lessons learned and future opportunities in the rainbow nation Curr Pharmacogenomics Person Med 2011 9 3 191 207 22563365 PMC3228231
  28. [31]Fung KL Pan J Ohnuma S MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer Cancer Res 2014 74 2 598 608 24305879 PMC4784985
  29. [32]Wang H Ding K Zhang Y Jin L Kullo IJ He F Comparative and evolutionary pharmacogenetics of ABCB1: complex signatures of positive selection on coding and regulatory regions Pharmacogenet Genomics 2007 17 8 667 678 17622943
  30. [33]Tang M-X Cross P Andrews H Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan Neurology 2001 56 1 49 56 11148235
  31. [34]Zissimopoulos J Crimmins E St Clair P The value of delaying Alzheimer’s disease onset Forum Health Econ Policy 2014 18 1 25 39 27134606 PMC4851168

Cited by

Sorted by citations

Metadata

Authors
Zissimopoulos, J. M., Barthold, D., Brinton, R. D., & Joyce, G.
Affiliations
  • Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles
  • Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles2Center for Innovation in Brain Science, University of Arizona Health Sciences, Tucson
Venue
JAMA Neurology
Publisher
American Medical Association (AMA)
Published
2017-02-01
Volume
74
Issue
2
Pages
225
ISSN
2168-6149
DOI
10.1001/jamaneurol.2016.3783
PMC
PMC5646357
Cited by
163
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review